Callos Andrew 4

What Happened Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), reported an open-market sale of 1,930 shares on 2026-03-18 at $62.07 per share, resulting in proceeds of approximately $119,795. The transaction is recorded as a sale (transaction code S) and does not indicate a purchase or option exercise.

Key Details

• Transaction date: 2026-03-18
• Price per share: $62.07
• Shares sold: 1,930
• Gross proceeds: ~$119,795
• Transaction type: Open market sale (code S)
• Shares owned after transaction: Not disclosed in the filing
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other footnotes were reported in the provided transaction detail
• Timeliness: Filing and period of report are dated 2026-03-18 — appears to have been filed timely (no late filing flag)

Context Sales by executives can be routine (diversification, liquidity, tax reasons) and do not alone indicate positive or negative views on the company—only purchases tend to be interpreted more directly as bullish signals. This Form 4 reports a straightforward open-market sale; there’s no indication of an option exercise, gift, or planned-sale program in the disclosed details.